her2 negative - Robuta Search

https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2024-09124 Datopotamab Deruxtecan and Trastuzumab Deruxtecan for the Treatment of HER2-Negative Unresectable,... Datopotamab Deruxtecan and Trastuzumab Deruxtecan for the Treatment of HER2-Negative Unresectable, Locally Advanced or Metastatic Breast Cancer datopotamab deruxtecan for the her2 negative trastuzumab https://www.esmo.org/meeting-calendar/esmo-breast-cancer-2023/industry-sponsored-satellite-symposia/perspectives-on-the-treatment-of-her2-negative-gbrcam-early-breast-cancer Perspectives on the Treatment of HER2-Negative gBRCAm Early Breast Cancer | ESMO early breast cancer on the her2 negative https://www.upmc.com/conditions/h/her2-negative-breast-cancer HER2-Negative Breast Cancer: Causes, Symptoms, and Treatments HER2-negative (HER2-) breast cancer, a type of breast cancer diagnosed when the cancer cells lack HER2 proteins. Find treatment options with UPMC. her2 negative breast cancer causes symptoms treatments https://www.hmpgloballearningnetwork.com/site/jcp/videos/hr-positive-and-her2-negative-breast-cancer-treatment-updates HR-Positive and HER2-Negative Breast Cancer Treatment Updates William J. Gradishar, MD, details the latest advancements in the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor... her2 negative breast cancer hr positive treatment updates https://www.researchandmarkets.com/reports/6115141/her2-negative-breast-cancer-epidemiology-forecast HER2-Negative Breast Cancer: Epidemiology Forecast to 2034 Breast cancer is a malignant tumor originating within the breast tissue. The most common type of breast cancer is invasive breast cancer, which originates... her2 negative breast cancer epidemiology forecast 2034 https://www.hmpgloballearningnetwork.com/site/onc/news/bireociclib-plus-fulvestrant-hr-positive-her2-negative-advanced-breast-cancer Bireociclib Plus Fulvestrant in HR-Positive, HER2-Negative Advanced Breast Cancer Final results from the phase 3 BRIGHT-2 trial demonstrated that bireociclib plus fulvestrant significantly improves PFS compared with fulvestrant alone in... in hr her2 negative plus fulvestrant https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-imlunestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast FDA approves imlunestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic... On September 25, 2025, the Food and Drug Administration approved imlunestrant (Inluriyo, Eli Lilly and Company), an estrogen receptor antagonist, for adults... https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-everolimus-letrozole-exemestane-advanced-her2-negative-breast-cancer-bolero-4 A trial of everolimus, letrozole and exemestane for advanced HER2 negative breast cancer (BOLERO 4) This trial looked at adding everolimus to letrozole and exemestane for breast cancer. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-imlunestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast?ref=onyxnewsroom.com FDA approves imlunestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic... On September 25, 2025, the Food and Drug Administration approved imlunestrant (Inluriyo, Eli Lilly and Company), an estrogen receptor antagonist, for adults... https://www.aacr.org/about-the-aacr/newsroom/news-releases/hr-positive-her2-negative-breast-cancer-patients-with-high-risk-of-recurrence-may-benefit-from-addition-of-anthracyclines-to-taxane-based-chemotherapy/ HR-positive, HER2-negative Breast Cancer Patients With High Risk of Recurrence May Benefit From... Dec 13, 2024 - Genomic testing helped identify which patients with node-negative, HR-positive, HER2- negative breast cancer could benefit from the addition of anthracyclines... her2 negative breast cancer https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2023-11062 Datopotamab-Deruxtecan for the Treatment of Patients with HER2 Negative Breast Cancer with Brain... Datopotamab-Deruxtecan for the Treatment of Patients with HER2 Negative Breast Cancer with Brain Metastasis her2 negative breast cancer https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-buparlisib-with-paclitaxel-for-advanced-her2-negative-breast-cancer-belle4 A trial of buparlisib and paclitaxel for advanced HER2 negative breast cancer (BELLE 4) This trial looked at adding buparlisib to paclitaxel for breast cancer that is HER2 negative. her2 negative breast cancer https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-vepdegestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast FDA approves vepdegestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic... FDA approves vepdegestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer https://www.biospace.com/puma-biotechnology-announces-phase-ii-clinical-trial-design-for-alisertib-in-her2-negative-hormone-receptor-positive-metastatic-breast-cancer Puma Biotechnology Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone... Dec 11, 2023 - Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company (the Company), announced the design of the Phase II trial of alisertib for the treatment... phase ii clinical trial https://www.breastcancer.org/podcast/kisqali-monaleesa-2 Kisqali Plus Femara Seems Best Option for Advanced-Stage Hormone-Receptor-Positive HER2-Negative... Dr. Gabriel Hortobagyi discusses overall survival results from the MONALEESA-2 trial. https://www.breastcancer.org/research-news/lynparza-approved-for-her2-neg-brca-mets Lynparza Approved to Treat Metastatic HER2-Negative Breast Cancer in Women With BRCA Mutations On Jan. 12, 2018, the FDA approved Lynparza to treat metastatic HER2-negative breast cancer in women with a BRCA1 or BRCA2 mutation. her2 negative breast cancer https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2025-06351&r=1 Avasopasem for the Treatment of Patients with Metastatic Hormone Receptor Positive, HER2 Negative... Avasopasem for the Treatment of Patients with Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer with Progression on a CDK4/6 Inhibitor and... https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-at-onartuzumab-with-chemotherapy-for-her2-negative-cancer-of-stomach-or-gastro-oesophageal-junction A trial looking at onartuzumab with chemotherapy for HER2 negative cancer of the stomach or where... This trial looked at the combination of onartuzumab and chemotherapy. It was for people with either stomach cancer or gastro oesophageal junction. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-chemotherapy-her2-negative-gastric-or-gastroesophageal-junction FDA approves pembrolizumab with chemotherapy for HER2-negative gastric or gastroesophageal junction... On November 16, 2023, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with fluoropyrimidine- and platinum-containing chemotherapy for... https://www.cancer.gov/publications/dictionaries/cancer-terms/def/er-negative-pr-negative-her2-neu-negative-breast-cancer Definition of ER-negative PR-negative HER2/neu-negative breast cancer - NCI Dictionary of Cancer... NCI's Dictionary of Cancer Terms provides easy-to-understand definitions for words and phrases related to cancer and medicine. definition of er negative her2 neu breast cancer pr https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1272602/full Frontiers | Treatment options for patients with hormone receptor-positive, HER2-negative... Breast cancer is the most commonly diagnosed cancer in women worldwide. Over the past decade, the treatment paradigm for patients with metastatic breast canc... hormone receptor positive treatment options for patients frontiers